Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Defaulteron Mar 16, 2016 10:10pm
196 Views
Post# 24667867

UPDATE 1-Ackman sells part of Mondelez stake

UPDATE 1-Ackman sells part of Mondelez stake
BOSTON, March 16 (Reuters) - Billionaire investor William Ackman adjusted his battered hedge fund portfolio on Wednesday when he sold 20 million shares of snack maker Mondelez International, one day after another key holding, Valeant Pharmaceuticals, lost half of its value. In a three paragraph letter sent to investors after the close of trading on Wednesday and seen by Reuters, Ackman said his firm, Pershing Square, has no plans to sell other investments right now and has "substantial uninvested cash." The letter came one day after Pershing Square lost about $800 million when Valeant was pummeled after raising the possibility that it may default on its debt and posting a worse-than-expected financial outlook. Ackman's Pershing Square Holdings has now lost 26.4 percent since January, marking one of the worst performances in the hedge fund industry this year.
<< Previous
Bullboard Posts
Next >>